Mankind Pharma redeems ₹1,250 crore NCDs at maturity
- Mankind Pharma redeemed ₹1,250 crore NCDs at full maturity on October 16, 2026
- Total gross interest paid across two series amounted to ₹149.97 crore
- Outstanding balance for the redeemed series stands at zero post-maturity
- The remaining disclosed NCD series has an issue size of ₹2,500 crore
*this image is generated using AI for illustrative purposes only.
Mankind Pharma redeemed ₹1,250 crore worth of Non-Convertible Debentures (NCDs) at full maturity on October 16, 2026. The company simultaneously serviced interest obligations for two separate debenture series, ensuring zero outstanding balance for the redeemed tranche.
The redemption pertains to the ISIN ending in 07025, which had an issue size of ₹1,250 crore. The company confirmed the full redemption of 1,25,000 units. This action was taken pursuant to Regulation 57(1) of the SEBI Listing Regulations and aligns with the prior intimation dated September 23, 2026.
Interest Payments Serviced
In addition to the principal redemption, Mankind Pharma paid interest on two distinct NCD series. Both series operated on a half-yearly payment frequency. The record date for these payments was October 1, 2026, with the due date falling on the same day as the redemption, October 16, 2026.
The total gross interest amount paid across both series was ₹149.97 crore. The net amount after tax deductions stood at ₹149.83 crore. There were no delays or non-payments reported for either series.
| Series | Issue Size (₹ crore) | Gross Interest Paid (₹ crore) | Net Interest Paid (₹ crore) | Frequency |
|---|---|---|---|---|
| Series A | 1,250.00 | 50.07 | 49.97 | Half yearly |
| Series B | 2,500.00 | 99.90 | 99.86 | Half yearly |
Redemption Details
The redemption was executed strictly at maturity, with no premature calls or put options exercised. The following table summarizes the key redemption metrics for the matured tranche:
| Metric | Detail |
|---|---|
| Redemption Type | Full |
| Reason | Maturity |
| Units Redeemed | 1,25,000 |
| Amount Redeemed | ₹1,250 crore |
| Outstanding Balance | ₹0 |
| Actual Redemption Date | October 16, 2026 |
What the Numbers Show
The data reveals a significant divergence in liability management between the two disclosed NCD series. While the redeemed series (Series A) had an issue size of ₹1,250 crore, the second series (Series B), which remains outstanding, is twice as large at ₹2,500 crore. Despite the larger principal base of Series B, the interest burden difference is proportional to the size, indicating similar coupon rates across both tranches. The complete extinguishment of Series A reduces the immediate debt obligation by ₹1,250 crore, leaving the ₹2,500 crore Series B as the primary remaining debt instrument among those detailed in this filing.
Historical Stock Returns for Mankind Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.07% | -4.39% | -0.22% | +7.21% | -6.96% | +59.99% |
How will the ₹1,250 crore reduction in debt impact Mankind Pharma's upcoming capital expenditure plans and working capital requirements?
What are the maturity dates and refinancing strategies for the remaining ₹2,500 crore Series B NCDs to avoid future liquidity crunches?
Will the successful redemption of this tranche lead to an upgrade in Mankind Pharma's credit rating or lower borrowing costs for future debt issuances?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
